AbbVie Inc. (NYSE:ABBV) saw unusually large options trading on Monday. Investors acquired 278 put options on the company. This represents an increase of approximately 121% compared to the typical daily volume of 126 put options.

AbbVie (NYSE ABBV) opened at 72.59 on Thursday. The firm’s 50-day moving average price is $71.63 and its 200-day moving average price is $65.94. AbbVie has a 1-year low of $55.06 and a 1-year high of $75.04. The firm has a market cap of $115.53 billion, a P/E ratio of 18.82 and a beta of 1.51.

AbbVie (NYSE:ABBV) last released its earnings results on Thursday, April 27th. The company reported $1.28 earnings per share for the quarter, beating analysts’ consensus estimates of $1.26 by $0.02. The company had revenue of $6.54 billion for the quarter, compared to analysts’ expectations of $6.49 billion. AbbVie had a net margin of 24.07% and a return on equity of 148.83%. AbbVie’s revenue for the quarter was up 9.7% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.15 EPS. Equities research analysts anticipate that AbbVie will post $5.53 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, August 15th. Shareholders of record on Friday, July 14th will be issued a $0.64 dividend. The ex-dividend date of this dividend is Wednesday, July 12th. This represents a $2.56 dividend on an annualized basis and a yield of 3.53%. AbbVie’s dividend payout ratio is currently 66.32%.

In other AbbVie news, insider Laura J. Schumacher sold 79,800 shares of the firm’s stock in a transaction on Wednesday, June 14th. The stock was sold at an average price of $70.00, for a total transaction of $5,586,000.00. Following the transaction, the insider now owns 187,625 shares in the company, valued at approximately $13,133,750. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO William J. Chase sold 38,300 shares of the firm’s stock in a transaction on Thursday, May 18th. The stock was sold at an average price of $65.35, for a total value of $2,502,905.00. Following the transaction, the chief financial officer now owns 209,043 shares in the company, valued at approximately $13,660,960.05. The disclosure for this sale can be found here. In the last quarter, insiders have sold 278,135 shares of company stock worth $18,841,085. 0.23% of the stock is owned by corporate insiders.

A number of hedge funds have recently made changes to their positions in ABBV. Hanson & Doremus Investment Management increased its stake in shares of AbbVie by 1.0% in the second quarter. Hanson & Doremus Investment Management now owns 5,609 shares of the company’s stock worth $407,000 after buying an additional 57 shares in the last quarter. Municipal Employees Retirement System of Michigan increased its stake in shares of AbbVie by 3.6% in the second quarter. Municipal Employees Retirement System of Michigan now owns 95,440 shares of the company’s stock worth $6,920,000 after buying an additional 3,280 shares in the last quarter. Benjamin F. Edwards & Company Inc. increased its stake in shares of AbbVie by 46.0% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 21,598 shares of the company’s stock worth $1,566,000 after buying an additional 6,800 shares in the last quarter. Ferguson Wellman Capital Management Inc. increased its stake in shares of AbbVie by 8.4% in the second quarter. Ferguson Wellman Capital Management Inc. now owns 751,750 shares of the company’s stock worth $54,509,000 after buying an additional 58,554 shares in the last quarter. Finally, Park Avenue Securities LLC bought a new stake in shares of AbbVie during the second quarter worth about $351,000. Institutional investors own 68.08% of the company’s stock.

ABBV has been the topic of a number of research analyst reports. Vetr downgraded AbbVie from a “buy” rating to a “hold” rating and set a $76.28 target price on the stock. in a report on Thursday, July 20th. Leerink Swann reissued a “market perform” rating on shares of AbbVie in a report on Thursday, June 22nd. Deutsche Bank AG reaffirmed a “hold” rating and set a $66.00 target price (up from $65.00) on shares of AbbVie in a research report on Monday, July 17th. Jefferies Group LLC reaffirmed a “buy” rating and set a $94.00 target price (up from $92.00) on shares of AbbVie in a research report on Monday, July 17th. Finally, Credit Suisse Group reaffirmed a “neutral” rating and set a $74.00 target price (up from $65.00) on shares of AbbVie in a research report on Thursday, July 20th. Eight investment analysts have rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $74.52.

ILLEGAL ACTIVITY WARNING: “AbbVie Sees Unusually High Options Volume (ABBV)” was published by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright and trademark law. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/07/27/abbvie-sees-unusually-high-options-volume-abbv.html.

AbbVie Company Profile

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Receive News & Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related companies with MarketBeat.com's FREE daily email newsletter.